Keyphrases
Indonesia
100%
Tuberculosis Patients
91%
COVID-19
78%
Surabaya
61%
Pulmonary Tuberculosis
56%
Multidrug-resistant Tuberculosis (MDR-TB)
56%
Mycobacterium Tuberculosis (M. tb)
45%
Tuberculosis
44%
COVID-19 Patients
26%
Tuberculosis Treatment
22%
Meta-analysis
21%
Risk Factors
18%
Healthcare Workers
17%
Community-acquired Pneumonia
17%
Bedaquiline
17%
TB Patients
17%
Active Tuberculosis
16%
Sputum
16%
Asthma
16%
Acid-fast Bacilli
15%
Core Needle Biopsy
14%
Idiopathic Pulmonary Fibrosis
14%
Rifampicin
13%
Intensive Phase
13%
East Java Indonesia
13%
Indonesian
13%
Systematic Meta-analysis
12%
Interleukin-6
12%
Quality of Life
11%
Disease Severity
11%
Lung Damage
10%
Lung Tissue
10%
C-reactive Protein
10%
Mycobacterium Tuberculosis Complex
10%
Pulmonary TB Patients
10%
Comorbidity
10%
Electronic Nose (E-nose)
10%
Immune Response
9%
COVID-19 Vaccine
9%
Type 1 Diabetes Mellitus (T1DM)
9%
Lung
9%
Latent Tuberculosis Infection
9%
Co-infection
9%
Rifampicin-resistant Tuberculosis
9%
Melanoma Antigens
9%
Academic Hospital
9%
General Hospital
9%
Non-small Cell Lung Cancer (NSCLC)
8%
Antibody Response
8%
Mortality Risk
8%
Avian Influenza
8%
Lopinavir
8%
Tertiary Referral Hospital
8%
Delamanid
8%
GeneXpert
8%
Shorter Regimen
8%
Virus
8%
Severe Coronavirus Disease 2019
8%
Antibiotics
8%
Quantitative PCR
8%
Lung Cancer
8%
Pneumonia Patients
8%
Bronchoalveolar Lavage
8%
Forceps Biopsy
8%
QTc Interval
8%
Medical Records
7%
Tuberculosis Diagnosis
7%
QT Prolongation
7%
Hypertension
7%
N-acetyltransferase 2 (NAT2)
7%
Moxifloxacin
7%
Chest X-ray
7%
Treatment Group
7%
Interleukin-10
7%
Inflammatory Cytokines
7%
Serum Levels
7%
Lung Function
7%
Armpit
7%
Treatment Outcome
7%
Sputum Samples
7%
Body Mass Index
7%
Randomized Controlled Trial
7%
Macrophage Polarization
7%
Acute Respiratory Distress Syndrome
7%
In Vitro Study
6%
Asthma Symptoms
6%
Hospitalized Patients
6%
Obesity
6%
COPD Patients
6%
Mesenchymal Stem Cells
6%
Lung Tuberculosis
6%
Referral Hospital
6%
Adverse Effects
6%
Pulmonary Fibrosis
6%
Rifampicin Resistance
6%
Peak Expiratory Flow
6%
Critically Ill COVID-19 Patients
6%
Indonesian Patients
6%
Convalescent Plasma
6%
Chronic Obstructive Pulmonary Disease
6%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
73%
Lung Tuberculosis
52%
Coronavirinae
46%
Infection
35%
Drug Resistant Tuberculosis
26%
Mycobacterium Tuberculosis
23%
Tuberculosis
22%
Rifampicin
21%
Multi-Drug-Resistant Tuberculosis
18%
Asthma
18%
Bedaquiline
17%
SARS Coronavirus
16%
Tumor Necrosis Factor
15%
Prevalence
15%
Community Acquired Pneumonia
14%
Randomized Controlled Trial
13%
Side Effect
13%
COVID-19 Vaccine
12%
Comorbidity
12%
Interleukin 6
12%
Lung Injury
12%
Chronic Obstructive Lung Disease
12%
Biological Marker
11%
Acid Fast Bacterium
11%
Retrospective Study
11%
Diabetes Mellitus
10%
C Reactive Protein
10%
Non Small Cell Lung Cancer
10%
Latent Tuberculosis
8%
Fibrosing Alveolitis
8%
Lopinavir Plus Ritonavir
8%
Delamanid
8%
Mortality Rate
8%
Disease Severity
8%
Antibiotics
8%
Cytokine
8%
Inflammation
8%
Moxifloxacin
8%
Messenger RNA
7%
Tissue Injury
7%
Epidermal Growth Factor Receptor
7%
Lung Cancer
7%
Pharmacokinetics
7%
Mycobacterium Tuberculosis Complex
6%
Treatment Group
6%
Infectious Agent
6%
Adult Respiratory Distress Syndrome
6%
Lung Fibrosis
6%
Escherichia coli
6%
Receptor
6%
Cohort Study
6%
Quinolone Derivative
5%
Liver Injury
5%
Adenosine Deaminase
5%
Adenosine Receptor
5%
Chlorogenic Acid
5%
Extrapulmonary Tuberculosis
5%
Mixed Infection
5%
Vitamin D
5%
Combination Drug
5%
Hydroxychloroquine
5%
Coffea Canephora
5%
Helicobacter Pylori
5%
Pharmacotherapy
5%
Azithromycin
5%
Tuberculostatic Agent
5%
Mycobacteria
5%
Antivirus Agent
5%
Neoplasm
5%
Atypical Mycobacterium
5%
Medicine and Dentistry
COVID-19
70%
Lung Tuberculosis
36%
Sputum
25%
Infection
21%
Lung
19%
Mycobacterium Tuberculosis
18%
Biopsy Technique
18%
Diseases
17%
Asthma
15%
Severe Acute Respiratory Syndrome Coronavirus 2
14%
Systematic Review
14%
Drug Resistant Tuberculosis
14%
Multidrug Resistant Tuberculosis
14%
Prevalence
13%
Meta-Analysis
12%
Mixed Infection
12%
Community-Acquired Pneumonia
11%
Acid Fast Bacterium
10%
Randomized Controlled Trial
10%
Non Small Cell Lung Cancer
10%
Diagnosis
10%
COVID-19 Vaccine
9%
Lung Tumor
9%
Sweat
8%
Bedaquiline
8%
Tuberculosis
8%
Tuberculostatic Agent
8%
Lung Cancer
7%
Interleukin 6
7%
Extrapulmonary Tuberculosis
7%
Retrospective Study
6%
Tumor Necrosis Factor
6%
Patient Referral
6%
Biological Marker
6%
Mortality Rate
6%
Chest Radiograph
6%
Idiopathic Pulmonary Fibrosis
5%
Epidermal Growth Factor Receptor
5%
Rifampicin
5%
Melanoma Antigen
5%
Liver Injury
5%
Antibody Response
5%
Heligmosomoides polygyrus
5%
Epitope
5%
Adenosine Deaminase
5%
Delamanid
5%
Lymphocyte
5%
Tuberculosis Treatment
5%
Immune Response
5%
Comorbidity
5%
Diabetes Mellitus
5%
Adverse Effect
5%
Medical Record
5%
Health Care
5%
COVID-19 Vaccination
5%